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The deployment of adenovirus serotype 5 (Ad5)-based vectors is hampered by preexisting immunity. When
such vectors are delivered intravenously, hepatocyte transduction is mediated by the hexon-coagulation factor
X (FX) interaction. Here, we demonstrate that human sera efficiently block FX-mediated cellular binding and
transduction of Ad5-based vectors in vitro. Neutralizing activity correlated well with the ability to inhibit
Ad5-mediated liver transduction, suggesting that prescreening patient sera in this manner accurately predicts
the efficacy of Ad5-based gene therapies. Neutralization in vitro can be partially bypassed by pseudotyping with
Ad45 fiber protein, indicating that a proportion of neutralizing antibodies are directed against the Ad5 fiber.
Adenoviruses, particularly those based on adenovirus sero-
type 5 (Ad5), are used for a variety of gene delivery applica-
tions both in vitro and in vivo, since they efficiently transduce
a wide range of cell types. In vitro, primary cell tethering
involves the Ad5 fiber knob domain engaging coxsackievirus
and adenovirus receptors (CAR) (3). Once bound, the flexible
fiber protein bends, allowing a secondary, uptake-stimulating
interaction to occur between recruited v3/v5 integrins and
RGD motifs in the penton base (28). When introduced sys-
temically, the transduction profile of Ad5, characterized by
extensive hepatocyte transduction, does not correlate with ex-
pression of CAR, which is limited to the tight junctions (5).
Furthermore, the introduction of mutations within the fiber
knob domain that abrogate CAR binding and infectivity in
vitro has no discernible effect on Ad5 biodistribution and
transduction profiles in vivo following intravenous delivery (1,
10). Together, these observations suggested that Ad5-medi-
ated transduction of hepatocytes operate via a CAR-indepen-
dent pathway. Recently, several studies (7, 11, 12, 16, 17, 24,
26, 27) have suggested a fundamental involvement of host
proteins, notably coagulation factors, in dictating adenoviral
infectivity in vivo. Pivotal to hepatic transduction is the inter-
action between the Ad5 hexon protein and the coagulation
factor X (FX) (7, 24, 26), which serves to “bridge” the Ad5-FX
complex to alternative receptors, which are expressed abun-
dantly within the liver. Hepatocyte transduction can be abol-
ished by using warfarin (7, 12, 16, 27) to prevent the gamma
carboxylation of glutamic acid residues in the N-terminal
-carboxyglutamic acid (Gla) domain of FX; the snake venom-
derived protein X-bp (2), which binds the Gla domain of FX,
inhibiting its interaction with hexon (26); or hexon chimeric or
mutated Ad5 vectors to abrogate FX binding (7, 24, 26).
Forty-five to fifty percent of individuals in the United States
possess high levels of neutralizing antibodies (NAbs) against
the Ad5 vector, with even higher seroprevalence rates ob-
served among Asian and African populations (21). NAbs as-
sociate with the capsid, preventing transduction of the target
cell (19, 20) and limiting its efficacy for gene transfer in vivo
(8), while serving to prime a robust immunological response
against the vector (4). Existing assays for the detection of NAbs
are based on inhibiting CAR-mediated uptake (6, 9, 13, 19), a
pathway that appears to be redundant for intravenous target-
ing (12, 26). Since several previous studies have implicated the
hexon protein as the major site of immunogenicity on the Ad5
capsid (14, 15, 21, 30), we reasoned that it would be important
to assess the effects of neutralizing sera on cellular uptake
mediated via the hexon-FX pathway. We considered that ex-
amining the effects of sera on FX-mediated uptake would
better predict the clinical efficacy of Ad5-based vectors when
delivered systemically and would show improved sensitivity
compared with that of existing assays.
To examine the neutralizing capacity of patient sera on FX-
mediated Ad5 uptake, we examined the capacity of Ad5 to
bind and infect the human hepatoma cell line (HepG2) in
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vitro, in the presence of both physiological concentrations of
FX (8 g/ml) and 2.5% neutralizing sera. Since liver infectivity
in vivo is not mediated via the CAR pathway, we utilized the
CAR-binding ablated vector AdKO1 (18) for in vitro studies to
best replicate the in vivo setting. Forty-eight hours postinfec-
tion, reporter transgene activity (-galactosidase [-Gal]) was
quantified (Fig. 1). All sera tested had previously been evalu-
ated for the presence of NAbs by using existing assays based on
the infectivity of Ad5 in A549 cells, with sera 1, 2, 3, 4, 5, 23, 24,
26, and 27 all scoring negative for neutralization (Table 1). The
majority of sera that had previously tested positive for neutral-
izing activity using the CAR-based infectivity assay in A549
cells also efficiently neutralized FX-mediated Ad5 transduc-
tion. However, four of the sera (sera 2, 4, 23, and 27) which had
previously been scored negative for neutralization by the CAR-
based infectivity assays in A549 cells neutralized efficiently in
the FX-based assay. To examine whether this neutralizing ca-
pacity correlated with a decreased level of binding of virions to
cell surfaces, we performed cell tethering studies at 4°C as
described previously (Fig. 1) (11). For the majority of sera
tested, low levels of transduction correlated well with de-
creased levels of cell binding. Several sera (for example, sera 8,
10, 40, and 54), however, demonstrated considerable levels of
cell association in the absence of transduction, indicating that
neutralization is likely to have occurred at a post-cell binding
step, as has been observed previously for some NAbs (23).
To further evaluate the sensitivity of the FX-mediated neu-
tralization assay for detecting NAbs, we performed assays in
the presence of FX and limiting dilutions of sera (Fig. 2) that
neutralize in both FX- and CAR-based assays (sera 14 and 16),
that neutralize poorly in both assays (sera 1 and 26), or that
neutralize in the FX- but not the CAR-based assay (sera 2 and
FIG. 1. Effect of neutralizing sera on FX-mediated Ad5 cell bind-
ing and transduction. HepG2 cells were infected with 1,000 vp/cell of
AdKO1 in the presence of 1 IU/ml of FX and 2.5% sera from patients
previously screened for anti-Ad NAbs and stained for expression of the
-Gal reporter gene 48 h postinfection. Controls were cells only or
virus in the presence or absence of FX (in the absence of serum). RLU,
relative light units. Quantification of cell transduction (bars) and bind-
ing (diamonds) of Ad5 in the presence of neutralizing sera was per-
formed. A binding assay was performed as described previously (11),
quantifying the binding of Ad5 to HepG2 cells following 1 h of incu-
bation at 4°C. Vector genomes were detected by quantitative PCR,
using the LacZ-specific primers 5-ATCTGACCACCAGCGAAATG
G-3 and 5-CATCAGCAGGTGTATCTGCCG-3.
TABLE 1. Effect of neutralizing sera on CAR-mediated
Ad5 transductiona
Sera no. % Sera required to inhibit Luc expressionby 90% in A549 cells NAb status
1 >25 
2 >25 
3 >25 
4 >25 
5 >25 
6 6.7 
7 1.6 
8 7.5 
9 2.3 
10 2.8 
11 5.7 
12 2.3 
13 1.9 
14 2.1 
15 5.8 
16 1.6 
17 9.0 
18 9.1 
19 7.3 
20 2.5 
21 4.3 
22 2.4 
23 >25 
24 >25 
25 1.6 
26 >25 
27 >25 
28 4.2 
29 3.0 
30 1.6 
31 5.4 
32 5.4 
33 2.6 
34 5.1 
35 5.6 
36 1.6 
37 7.5 
38 1.6 
39 1.6 
40 1.6 
41 4.2 
42 1.6 
43 1.6 
44 3.0 
45 4.7 
46 2.8 
47 1.9 
48 3.4 
49 1.8 
50 3.8 
51 3.9 
52 3.0 
53 1.6 
54 1.6 
55 5.2 
56 1.6 
57 6.1 
58 1.6 
59 3.0 
60 1.6 
61 8.2 
62 4.0 
a A549 cells were transduced with Ad5 in the presence of sera derived from 62
individuals. The percentage of sera required to inhibit luciferase (Luc) by 90%
was gauged. Sera which failed to inhibit 90% of luciferase expression in 25%
sera (the highest concentration of sera tested) were considered negative for
neutralizing antibodies (boldface).
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4). Serum 1 showed detectable but weak neutralization (30%
at a 2.5% dilution), while serum 26 showed no neutralization at
any dilution. While strong neutralization of transgene expres-
sion was noted for sera 14 and 16, sera 2 and 4 showed more
intermediate neutralization of transduction. These data sug-
gest that neutralization appears more pronounced via the FX-
based assay and that this assay might be more relevant for
gauging the efficacy of Ad-based vectors designed for applica-
tion via the systemic route.
To determine the effects of NAbs on transduction of hepa-
tocytes in vivo following systemic delivery, mice were given
Ad5 in the presence or absence of selected neutralizing sera. In
order to maintain a serum/virus ratio consistent with the in
vitro experiments and to avoid injecting large volumes of sera,
we elected to administer 1  109 viral particles (vp) of Ad5
with and without 125 l undiluted neutralizing sera. To facil-
itate transduction of hepatocytes at such low virus doses, mice
were transiently depleted of macrophages by pretreatment
with 200 l of liposomal clodronate 24 h prior to the admin-
istration of the virus-serum (22). In the absence of neutralizing
sera, Ad5 mediated high levels of transduction in the liver (Fig.
3). In the presence of serum 14 (a highly neutralizing serum in
vitro), transduction in the liver was completely ablated, indi-
cating that efficient viral neutralization had occurred, prevent-
ing infection of hepatocytes. Sera with intermediate (serum 27)
or minimal (serum 26) neutralizing activity in vitro demon-
strated levels of transduction that were intermediate between
the two extremes, indicating a partial neutralization of the
vector. These data demonstrate the enhanced sensitivity of the
in vitro FX-based neutralization assay in identifying serum
samples with potential anti-Ad5 activity relevant to systemic in
vivo gene therapy applications.
To evaluate whether pseudotyping the Ad5 vector with
fibers from an alternative and less-immunogenic serotype
(Ad45) might represent an effective strategy for bypassing
NAbs, neutralization experiments were performed using the
pseudotyped Ad vector Ad5/f45 (Fig. 4). Ad45 has been shown
previously to exhibit greatly reduced seroprevalence compared
with that of Ad5 (25), while the pseudotyped vector Ad5/f45
demonstrated substantial FX-mediated enhanced cell binding
and transduction (11). Surprisingly, we found that the
pseudotyped vector was able to mediate significant transgene
expression in the presence of a number of neutralizing sera,
suggesting that a significant proportion of NAbs appeared to
be directed against the Ad5 fiber protein. Of the 62 sera tested,
57 sera (91.9%) mediated 90% inhibition of transduction for
Ad5, whereas only 35 sera (56.5%) mediated 90% inhibition
of transduction for Ad5/f45 at the same dilution, suggesting
that a significant proportion of NAbs in human sera are di-
rected against the fiber protein and that antibody evasion
might be achieved (at least partially) by pseudotyping Ad5 with
fibers from less-immunogenic serotypes, rather than complete
FIG. 2. Effect of serum dilution on FX-mediated cellular transduction. HepG2 cells were infected with AdKO1 in the presence of 1 IU/ml of
FX and in the presence of doubling dilutions of selected neutralizing sera. Expression of the -Gal reporter was detected 48 h postinfection. RLU,
relative light units.
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serotype switching. Antibodies directed against the Ad5 fiber
protein may neutralize infectivity either by preventing cellular
attachment by interfering with the fiber knob-CAR receptor
interaction or by inducing the aggregation of virions, thereby
providing an extracellular means of neutralization (29).
Pseudotyping of Ad5 with the fiber protein from the less-
seroprevalent Ad45 may prevent neutralization by one or both
of these mechanisms.
Taken together, these data suggest that the neutralizing ac-
tivity of human sera can be accurately gauged via FX-mediated
FIG. 3. Effect of neutralizing sera on Ad-mediated transduction of hepatocytes in vivo. Outbred MF-1 mice were transiently depleted of
macrophages by the administration of 200 l of liposomal clodronate 24 h prior to the intravenous administration of 1  109 vp of Ad5 in the
presence or absence of 125 l of neutralizing sera from selected individuals. At 48 h, an intraperitoneal injection of luciferin was followed by in
vivo bioimaging with a Xenogen IVIS-50 cooled charge-coupled-device camera. Luciferase expression was quantitated as photon flux from the
upper abdomen (diamonds).
FIG. 4. Effect of neutralizing sera on FX-mediated cell infectivity of fiber-pseudotyped Ad vectors. HepG2 cells were infected with 1,000 vp/ml
of Ad5/f45 in the presence of 1 IU/ml of FX and 2.5% neutralizing sera. Reporter gene activity was quantified 48 h postinfection.
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uptake. The degree of neutralizing activity, as established by an
in vitro assay, appears to correlate with the efficiency of hepa-
tocyte transduction in vivo in the presence of neutralizing sera,
a trait that ultimately will be important when considering the
systemic application of Ad5-based vectors clinically. Further-
more, we note that the pseudotyping of Ad5 vectors with the
fiber protein from less-immunogenic serotypes resulted in a
markedly decreased ability of NAbs to limit FX-mediated he-
patocyte transduction, suggesting that fiber pseudotyping may,
at least partially, represent a strategy to overcome vector neu-
tralization following systemic administration.
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